# Core Biogenesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/core-biogenesis

- Industry: Biotechnology
- Headquarters: France
- Website: www.corebiogenesis.com
- Total disclosed funding: $14M
- Latest round: Series A (Jun 8, 2022)
- Investors on record: 5

## About

Core Biogenesis is a biotechnology company specializing in the bioproduction of recombinant proteins and peptides for life sciences and skincare applications using plant-based platforms.Founded in 2020 in France, Core Biogenesis focuses on bioproduction solutions for the life sciences sector. The company was established by Alexandre Reeber, Chouaib MEZIADI, and Maurice Moloney. Their latest funding round was a Series A in June 2022, raising EUR 10.031 mn, primarily led by XAnge with participation from Blue Horizon, Entrepreneur First, and Thia Ventures. Core Biogenesis has executed 2 deals to date and has a current valuation of EUR 43.566 mn.Core Biogenesis specializes in the bioproduction of high-value recombinant proteins and peptides, primarily designed for use in the life sciences and skincare sectors. Utilizing proprietary platform technology, the company employs plants as biofactories, allowing for precise production of peptides and proteins within the plant's oleosomes. This approach delivers advanced solutions in anti-aging skincare and regenerative medicine, catering particularly to markets in Europe and North America where demand for biotechnological ingredients is growing. Their clients include various skincare brands and pharmaceutical companies integrating these ingredients into their products.Core Biogenesis generates revenue through partnerships and direct sales of its bioproduced proteins and peptides to clients in the life science and skincare industries. The business model is primarily B2B, collaborating with skincare brands that formulate products using its proprietary ingredients. Pricing structures are customized based on client needs and product specifications, ensuring competitive offerings. Core Biogenesis's flagship products are integral to anti-aging skincare formulations, providing unique biotechnologically advanced ingredients that support sustainability.In March 2022, Core Biogenesis raised EUR 10 mn in Series A funding to expand its team and production capabilities at a new facility in Strasbourg, France. The company plans to enhance its product line with upcoming developments aimed at addressing market needs in life sciences and skincare. Core Biogenesis intends to penetrate new markets and geographic regions, particularly increasing its presence in North America by the end of 2023.

## Funding rounds

- Series A, Jun 8, 2022, $11M — XAnge, Entrepreneur First, Blue Horizon, Thia Ventures
- Seed, Dec 1, 2020, $3.2M — XAnge, Plug and Play, Entrepreneur First

## Investors

- XAnge (https://capitalatlas.ai/funds/xange) — Seed, Series A
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- Entrepreneur First (https://capitalatlas.ai/funds/entrepreneur-first) — Seed, Series A
- Blue Horizon (https://capitalatlas.ai/funds/blue-horizon) — Series A
- Thia Ventures (https://capitalatlas.ai/funds/thia-ventures) — Series A